Skip to content
About Us
Corporate Profile
Senior Management
Board of Directors
Advisors and EDBI Connect
Core Values
Careers
Why EDBI
Why EDBI
Impact
Value Creation
Focal Sectors
Focal Sectors
Investment Criteria
Portfolio
News
Contact Us
Menu
About Us
Corporate Profile
Senior Management
Board of Directors
Advisors and EDBI Connect
Core Values
Careers
Why EDBI
Why EDBI
Impact
Value Creation
Focal Sectors
Focal Sectors
Investment Criteria
Portfolio
News
Contact Us
Menu
About Us
Corporate Profile
Senior Management
Board of Directors
Advisors and EDBI Connect
Core Values
Careers
Why EDBI
Why EDBI
Impact
Value Creation
Focal Sectors
Focal Sectors
Investment Criteria
Portfolio
News
Contact Us
Contact us
S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase(HDAC) Inhibitor SB939
27 September 2010
Share on facebook
Share on twitter
Share on linkedin
S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)